The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Cancer Risk After Use of Recombinant Bone Morphogenetic Protein-2 for Spinal Arthrodesis
Abstract
BACKGROUND: Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a growth factor known to have in vitro effects on the growth and invasiveness of cancer. It has been approved by the U.S. Food and Drug Administration in limited doses for single-level anterior spinal arthrodesis, but it is commonly used off-label and at high doses. The effect of rhBMP-2 on the risk of cancer has been a concern. We sought to evaluate the risk of new cancers in patients receiving high-dose rhBMP-2. METHODS: We used publicly available data from a pivotal, multicenter, randomized controlled trial of patients with degenerative lumbar spine conditions who underwent a single-level instrumented posterolateral arthrodesis with either high-dose rhBMP-2 in a compression-resistant matrix (CRM) (rhBMP-2/CRM; n = 239) or autogenous bone graft (control group; n = 224). We compared the risks of new cancers in the rhBMP-2/CRM and control groups at two and five years after surgery. RESULTS: At two years, with 86% follow-up, there were fifteen new cancer events in eleven patients in the rhBMP-2/CRM group compared with two new cancer events in two patients in the control group treated with autogenous bone graft. The incidence rate of new cancer events per 100 person-years was 3.37 (95% confidence interval [CI], 1.89 to 5.56) in the rhBMP-2/CRM group at two years compared with 0.50 (95% CI, 0.06 to 1.80) in the control group. The incidence rate ratio was 6.75 (95% CI, 1.57 to 60.83; p = 0.0026) at two years. Calculated in terms of the number of patients with one or more cancer events two years after the surgery, the incidence rate per 100 person-years was 2.54 (95% CI, 1.27 to 4.54) in the rhBMP-2/CRM group compared with 0.50 (95% CI, 0.06 to 1.82) in the control group at two years; the incidence rate ratio was 5.04 (95% CI, 1.10 to 46.82; p = 0.0194). At five years, there was a 37% loss of follow-up, but a significantly greater incidence of cancer events was still observed in the rhBMP-2/CRM group. CONCLUSIONS: A high dose of 40 mg of rhBMP-2/CRM in lumbar spinal arthrodesis was associated with an increased risk of new cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267
TGFβ signalling: a complex web in cancer progression
Ikushima, H., & Miyazono, K. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2853 · Cited by 1,173
TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.01.046 · Cited by 952
A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis
Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., Rondina, M. B., Guzzardo, V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.039 · Cited by 782
Cahill, K. S. (2009) · JAMA · doi:10.1001/jama.2009.956 · Cited by 489
Lonardo, E., Hermann, P. C., Mueller, M.-T., Huber, S., Balic, A., Miranda-Lorenzo, I., Zagorac, S., Alcala, S., Rodriguez-Arabaolaza, I., Ramirez, J. C., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.10.001 · Cited by 405
Safety Profile for the Clinical Use of Bone Morphogenetic Proteins in the Spine
Poynton, A. R., & Lane, J. M. (2002) · Spine · doi:10.1097/00007632-200208151-00010 · Cited by 403
Cited by
A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2
James, A. W., LaChaud, G., Shen, J., Asatrian, G., Nguyen, V., Zhang, X., Ting, K., & Soo, C. (2016) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2015.0357 · Cited by 1,131
Extracellular matrix-inspired growth factor delivery systems for bone regeneration
Martino, M. M., Briquez, P. S., Maruyama, K., & Hubbell, J. A. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.007 · Cited by 261
Formulation, Delivery and Stability of Bone Morphogenetic Proteins for Effective Bone Regeneration
El Bialy, I., Jiskoot, W., & Reza Nejadnik, M. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2147-x · Cited by 257
In Vitro and In Vivo study of naturally derived alginate/hydroxyapatite bio composite scaffolds
Mahmoud, E. M., Sayed, M., El-Kady, A. M., Elsayed, H., & Naga, S. M. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.10.014 · Cited by 79
Effect of age on biomaterial-mediated in situ bone tissue regeneration
Liu, M., Nakasaki, M., Shih, Y.-R. V., & Varghese, S. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.06.035 · Cited by 52
Metadata
- Authors
- Carragee, E. J., Chu, G., Rohatgi, R., Hurwitz, E. L., Weiner, B. K., Yoon, S. T., Comer, G., & Kopjar, B.
- Venue
- Journal of Bone and Joint Surgery
- Published
- 2013-09-04
- Volume
- 95
- Issue
- 17
- Pages
- 1537-1545
- ISSN
- 0021-9355 (ISSN-L)
- 1535-1386
- OpenAlex
- W2036939647
- Cited by
- 261
- References
- 21
- FWCI
- 18.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer Risk After Use of Recombinant Bone Morphogenetic Protein-2 for Spinal Arthrodesis. https://app.cochat.ai/papers/10.2106/jbjs.l.01483
- The paper
- Carragee, E. J., Chu, G., Rohatgi, R., Hurwitz, E. L., Weiner, B. K., Yoon, S. T., Comer, G., & Kopjar, B. (2013). Cancer Risk After Use of Recombinant Bone Morphogenetic Protein-2 for Spinal Arthrodesis. Journal of Bone and Joint Surgery. https://doi.org/10.2106/jbjs.l.01483
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
